Yet, paradoxically, RUNX3 appears to function as an oncogene in leukemia, basal cell carcinoma, ovarian cancer, head and neck cancer, and pancreatic cancer (8–12). This evidence concerns the gene RUNX3 and basal cell carcinoma.